Circulating Tumour DNA in Melanoma-Clinic Ready?

被引：29

作者：

Tivey, Ann ^{[1
,2
]}

Britton, Fiona ^{[1
]}

Scott, Julie-Ann ^{[1
]}

Rothwell, Dominic ^{[2
,3
]}

Lorigan, Paul ^{[1
,2
]}

Lee, Rebecca ^{[1
,2
,4
]}

机构：

[1] Christie NHS Fdn Trust, Wilmslow Rd, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, Div Canc Sci, Oxford Rd, Manchester M13 9PL, Lancs, England

[3] Univ Manchester, Canc Biomarker Ctr, Nucle Acids Biomarker Team, Canc Res UK Manchester Inst, Alderley Pk SK10 4TG, England

[4] Christie NHS Fdn Trust, Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England

来源：

CURRENT ONCOLOGY REPORTS | 2022年 / 24卷 / 03期

关键词：

ctDNA; Liquid biopsies; Melanoma; Immunotherapy; Targeted therapy; Biomarkers; STAGE-III MELANOMA; PREDICTS SURVIVAL; MEK INHIBITION; CANCER; BRAF; PLASMA; GENES;

D O I：

10.1007/s11912-021-01151-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review Liquid biopsies, including circulating tumour DNA (ctDNA), can inform a variety of clinical questions. This review examines the potential role of ctDNA as a clinical tool to inform clinical decision-making from early to late stage cutaneous melanoma. Recent Findings In pre-clinical studies, ctDNA has been shown to detect minimal residual disease and molecular relapse; predict and monitor response to therapy; and identify key resistance mechanisms. Here, we examine the potential utility of ctDNA and discuss its limitations for use in patients with melanoma. We present novel clinical trials, which are testing its value as a tool to augment clinical decision-making. Finally, we discuss the steps that are needed to ensure that ctDNA is used optimally in order to improve outcomes for patients with melanoma. Summary Preclinical studies have shown that ctDNA has huge potential to provide real-time information about disease status in patients with melanoma. It is now time to test it rigorously within clinical trials to assess how it can be optimally used to benefit patients in the clinic.

引用

页码：363 / 373

页数：11

共 70 条

[1] Continuous versus intermittent BRAF and MEK inhibition in patients withBRAF-mutated melanoma: a randomized phase 2 trial [J].

Algazi, Alain P. ;

Othus, Megan ;

Daud, Adil, I ;

Lo, Roger S. ;

Mehnert, Janice M. ;

Thach-Giao Truong ;

Conry, Robert ;

Kendra, Kari ;

Doolittle, Gary C. ;

Clark, Joseph, I ;

Messino, Michael J. ;

Moore, Dennis F., Jr. ;

Lao, Christopher ;

Faller, Bryan A. ;

Govindarajan, Rangaswamy ;

Harker-Murray, Amy ;

Dreisbach, Luke ;

Moon, James ;

Grossmann, Kenneth F. ;

Ribas, Antoni .

NATURE MEDICINE, 2020, 26 (10) :1564-+

[2] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma [J].

Ascierto, Paolo A. ;

Minor, David ;

Ribas, Antoni ;

Lebbe, Celeste ;

O'Hagan, Anne ;

Arya, Niki ;

Guckert, Mary ;

Schadendorf, Dirk ;

Kefford, Richard F. ;

Grob, Jean-Jacques ;

Hamid, Omid ;

Amaravadi, Ravi ;

Simeone, Ester ;

Wilhelm, Tabea ;

Kim, Kevin B. ;

Long, Georgina V. ;

Martin, Anne-Marie ;

Mazumdar, Jolly ;

Goodman, Vicki L. ;

Trefzer, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3205-+

[3] Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease [J].

Ballester, Leomar Y. ;

Oliva, Isabella C. Glitza ;

Douse, Dzifa Y. ;

Chen, Melissa M. ;

Lan, Chieh ;

Haydu, Lauren E. ;

Huse, Jason T. ;

Roy-Chowdhuri, Sinchita ;

Luthra, Rajyalakshmi ;

Wistuba, Ignacio I. ;

Davies, Michael A. .

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2018, 77 (07) :628-635

[4] Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function [J].

Boni, Andrea ;

Cogdill, Alexandria P. ;

Dang, Ping ;

Udayakumar, Durga ;

Njauw, Ching-Ni Jenny ;

Sloss, Callum M. ;

Ferrone, Cristina R. ;

Flaherty, Keith T. ;

Lawrence, Donald P. ;

Fisher, David E. ;

Tsao, Hensin ;

Wargo, Jennifer A. .

CANCER RESEARCH, 2010, 70 (13) :5213-5219

[5] Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma [J].

Braune, Jan ;

Keller, Laura ;

Schiller, Florian ;

Graf, Erika ;

Rafei-Shamsabadi, David ;

Wehrle, Julius ;

Follo, Marie ;

Philipp, Ulrike ;

Hussung, Saskia ;

Pfeifer, Dietmar ;

Mix, Michael ;

Duyster, Justus ;

Fritsch, Ralph ;

von Bubnoff, Dagmar ;

Meiss, Frank ;

von Bubnoff, Nikolas .

JCO PRECISION ONCOLOGY, 2020, 4 :20-31

[6] Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression [J].

Chang, Gregory A. ;

Taclepalli, Jyothirmayee S. ;

Shao, Yongzhao ;

Zhang, Yilong ;

Weiss, Sarah ;

Robinson, Eric ;

Spittle, Cindy ;

Furtado, Manohar ;

Shelton, Dawne N. ;

Karlin-Neumann, George ;

Pavlick, Anna ;

Osman, Iman ;

Polsky, David .

MOLECULAR ONCOLOGY, 2016, 10 (01) :157-165

[7] The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells [J].

Choi, JJ ;

Reich, CF ;

Pisetsky, DS .

IMMUNOLOGY, 2005, 115 (01) :55-62

[8] Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy [J].

da Silva, Ines Pires ;

Lo, Serigne ;

Quek, Camelia ;

Gonzalez, Maria ;

Carlino, Matteo S. ;

Long, Georgina, V ;

Menzies, Alexander M. .

CANCER, 2020, 126 (01) :86-97

[9] Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma [J].

De Mattos-Arruda, Leticia ;

Mayor, Regina ;

Ng, Charlotte K. Y. ;

Weigelt, Britta ;

Martinez-Ricarte, Francisco ;

Torrejon, Davis ;

Oliveira, Mafalda ;

Arias, Alexandra ;

Raventos, Carolina ;

Tang, Jiabin ;

Guerini-Rocco, Elena ;

Martinez-Saez, Elena ;

Lois, Sergio ;

Marin, Oscar ;

de la Cruz, Xavier ;

Piscuoglio, Salvatore ;

Towers, Russel ;

Vivancos, Ana ;

Peg, Vicente ;

Ramon y Cajal, Santiago ;

Carles, Joan ;

Rodon, Jordi ;

Gonzalez-Cao, Maria ;

Tabernero, Josep ;

Felip, Enriqueta ;

Sahuquillo, Joan ;

Berger, Michael F. ;

Cortes, Javier ;

Reis-Filho, Jorge S. ;

Seoane, Joan .

NATURE COMMUNICATIONS, 2015, 6

[10] Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma [J].

Dummer, Reinhard ;

Hauschild, Axel ;

Santinami, Mario ;

Atkinson, Victoria ;

Mandala, Mario ;

Kirkwood, John M. ;

Sileni, Vanna Chiarion ;

Larkin, James ;

Nyakas, Marta ;

Dutriaux, Caroline ;

Haydon, Andrew ;

Robert, Caroline ;

Mortier, Laurent ;

Schachter, Jacob ;

Lesimple, Thierry ;

Plummer, Ruth ;

Dasgupta, Kohinoor ;

Gasal, Eduard ;

Tan, Monique ;

Long, Georgina V. ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (12) :1139-1148

← 1 2 3 4 5 6 7 →